Western pharmaceutical companies developing new products have expressed interest in clinical sites within Central Europe, Eastern Europe and Russia for two compelling and interwoven reasons: speed and cost. Medical and economic features in this environment enhance the rate of study subject recruitment and, therefore, shorten total trial completion time and cost.

Western societies face increasing difficulty with trial enrollment because of trial entry exclusion criteria, competitive trials and investigator commitment issues. By contrast, nowhere in the world can one top the combination of highly skilled investigators and vast populations of treatment-naive subjects as found in Russia. Fees for the investigators and institutions within the state-operated public medical delivery systems of this region are notably competitive with those demanded in the United States and Western Europe. Russian investigators and subjects have proven essential to the completion of many recent large trials initiated in the West.

AmeRuss can simplify the process for the sponsor desiring a balance of preferred Western investigators with the advantages of affiliated enrollment in Russia.